Document Detail


Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.
MedLine Citation:
PMID:  20518600     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive therapy to treat seizures in Lennox-Gastaut syndrome in those 4 years of age and older. In this article, the putative mechanism of action is described, along with data relating to its pharmacokinetics and metabolism. Key findings from clinical trials are presented and discussed. Adverse effects are summarized and compared with those encountered with competitor antiepileptic drugs. Finally, the role of rufinamide in the holistic management of subjects with Lennox-Gastaut syndrome is considered.
Authors:
Colin D Ferrie
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  10     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-03     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  851-60     Citation Subset:  IM    
Affiliation:
Department of Paediatric Neurology, Paediatric Offices, Old Main Site (Block 16), A Floor, Leeds General Infirmary, Leeds, LS1 3EX, UK. colin.ferrie@leedsth.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticonvulsants / adverse effects,  pharmacology,  therapeutic use
Child
Clinical Trials as Topic
Epilepsy, Generalized / drug therapy*
Humans
Syndrome
Triazoles / adverse effects,  pharmacology*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Triazoles; 106308-44-5/rufinamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  News in brief.
Next Document:  Tapentadol immediate-release for acute pain.